Medication Overuse Headache (MOH), historically referred to as rebound headache, presents a frustrating clinical paradox: medications taken to relieve migraine pain can, when used too frequently, cause headaches to become more intense and frequent. Traditional abortive drugs, particularly triptans, opioids, and combination analgesics, carry a significant risk of inducing MOH if used more than 10 to 15 days per month.
Preventing MOH requires strict limits on acute drug intake and the introduction of effective daily preventive strategies. However, short-term prevention strategies using traditional triptans - such as frovatriptan protocols for predictable menstrual migraines - have faced scrutiny due to concerns over drug dependency and potential rebound cycles. This raised an important research question: could a CGRP receptor antagonist provide preventive relief without triggering medication overuse headaches?
Clinical trials evaluating CGRP receptor antagonists in patients with frequent migraine days provided valuable insights into this dynamic. Studies specifically excluded individuals taking acute headache medications on more than 10 days per month to ensure accurate baseline measurements. As patients were treated with CGRP antagonists, researchers tracked not only primary migraine frequency but also the number of days requiring acute rescue medications.
The data demonstrated that effective CGRP inhibition significantly reduced overall monthly headache frequency and substantially decreased the need for acute rescue drugs. Because CGRP antagonists do not induce receptor downregulation or rebound phenomena in the manner seen with chronic triptan or opioid exposure, they represent a mechanism capable of interrupting the cycle of medication overuse while simultaneously providing prophylactic control.